TEVA (STOCKS)
Teva Pharmaceutical Industries Limited American Depositary Shares
$34.125300
-0.504700 (-1.46%)
Prev close: $34.630000
Company Information
- Exchange
- XNYS
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Generic
- CEO
- Richard Francis
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $39,423.39M
- Employees
- 35,686
- P/E (TTM)
- 25.04
- P/B (TTM)
- 4.77
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
2
Strong Buy
4
Buy
1
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Mar 2026 (Q1)
|
$0.53 | $0.49 | +0.0428 | +8.78% |
|
Mar 2025 (Q4)
|
$0.96 | $0.69 | +0.2671 | +38.55% |
|
Sep 2025 (Q3)
|
$0.78 | $0.67 | +0.1105 | +16.50% |
|
Jun 2025 (Q2)
|
$0.66 | $0.63 | +0.0293 | +4.65% |
Financial Statements
| Revenues | $14.14B |
| Benefits Costs and Expenses | $11.35B |
| Cost Of Revenue | $8.32B |
| Costs And Expenses | $11.35B |
| Gross Profit | $9.03B |
| Nonoperating Income/Loss | -$925.00M |
| Operating Expenses | $6.75B |
| Depreciation and Amortization | $999.00M |
| Other Operating Expenses | $5.75B |
| Operating Income/Loss | $2.29B |
| Income/Loss Before Equity Method Investments | $1.37B |
| Income/Loss From Continuing Operations After Tax | $2.58B |
| Income/Loss From Continuing Operations Before Tax | $2.79B |
| Income/Loss From Equity Method Investments | $13.00M |
| Income Tax Expense/Benefit | -$187.00M |
| Net Income/Loss | $1.57B |
| Net Income/Loss Attributable To Noncontrolling Interest | $2.00M |
| Net Income/Loss Attributable To Parent | $1.56B |
| Net Income/Loss Available To Common Stockholders, Basic | $1.56B |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | $1.37 |
| Diluted Earnings Per Share | $1.33 |
| Basic Average Shares | 3,451,000,000 |
| Diluted Average Shares | 3,507,000,000 |
| Assets | $40.04B |
| Current Assets | $13.71B |
| Inventory | $3.18B |
| Prepaid Expenses | $1.07B |
| Other Current Assets | $9.46B |
| Noncurrent Assets | $26.33B |
| Fixed Assets | $4.00B |
| Other Non-current Assets | $22.33B |
| Liabilities | $31.81B |
| Current Liabilities | $13.53B |
| Wages | $555.00M |
| Other Current Liabilities | $12.98B |
| Noncurrent Liabilities | $18.28B |
| Equity | $8.23B |
| Equity Attributable To Noncontrolling Interest | $4.00M |
| Equity Attributable To Parent | $8.23B |
| Liabilities And Equity | $40.04B |
| Net Cash Flow From Operating Activities | $1.71B |
| Net Cash Flow From Operating Activities, Continuing | $1.71B |
| Net Cash Flow From Investing Activities | $765.00M |
| Net Cash Flow From Investing Activities, Continuing | $765.00M |
| Net Cash Flow From Financing Activities | -$394.00M |
| Net Cash Flow From Financing Activities, Continuing | -$394.00M |
| Exchange Gains/Losses | -$41.00M |
| Net Cash Flow | $2.04B |
| Net Cash Flow, Continuing | $2.09B |
| Comprehensive Income/Loss | $1.73B |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $1.00M |
| Comprehensive Income/Loss Attributable To Parent | $1.73B |
| Other Comprehensive Income/Loss | $163.00M |
| Other Comprehensive Income/Loss Attributable To Parent | $163.00M |